Back to search

France· FR:61853027

GLATIRAMER VIATRIS 20 mg/ml, solution injectable en seringue préremplie

A glatiramer acetate product containing acétate de glatiramère, registered in France by VIATRIS MEDICAL, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L03AX13

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedGLATIRAMER VIATRIS 20 mg/ml, solution…ATCL03AX13REGISTER NO.FR:61853027PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Glatiramer acetate is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AX13 (glatiramer acetate), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose

Glatiramer acetate · ATC L03AX13

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ACÉTATE DE GLATIRAMÈRE
Manufacturer
VIATRIS MEDICAL
Country
France (FR)
ATC code
L03AX13
ATC class
Glatiramer acetate
Defined daily dose
20 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930100943
    28 seringue(s) préremplie(s) en verre de 1 mL
    EUR 515.31

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for glatiramer acetate.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Glatiramer acetate · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • NatalizumabL04AA23severe
  • NatalizumabL04AG03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fc928e45-0ce8-40d8-9fc9-e3d35bbb4033
GET /v1/drugs/fc928e45-0ce8-40d8-9fc9-e3d35bbb4033?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61853027",
  "date_amm": "2017-05-24",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "ACÉTATE DE GLATIRAMÈRE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about glatiramer acetate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.